Table 1.

Clinical trials testing CAR T cell therapy in paediatric brain tumours.

Target	NCT Trial number	Trial Description	Tumour types	Age	Mode of delivery
IL13Rα2	04510051	Lymphodepletion followed by IL13Rα2 CAR T	Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumour, ATRT, Primitive Neuroectodermal Tumour, Choroid Plexus Carcinoma, Pineoblastoma	1 to 26 years	Intraventricular
IL13Rα2	02208362	Genetically modified CAR T cells in recurrent or refractory malignant glioma.	High grade glioma	12 to 75 years	Tumour or tumour resection cavity
GD2	04099797	C7R-GD2 CAR T Cells GD2-expressing HGG,DIPG or MB (GAIL-B)	Embryonal tumour, HGG or ependymal tumour with confirmed GD2-expression (or H3K27M+ for HGG)	1 to 18 years	Tumour or tumour resection cavity
GD2	04196413	GD2 CAR T for H3.3 mutated DMG or DIPG	H3-K27M-mutated DIPG or DMG of the spinal cord	2 years to 30 years	Systemic
HER2	02442297	HER2-specific CAR for HER2-Positive CNS Tumours (iCAR)	Primary CNS tumour or HER2 positive tumour metastatic to the CNS (exclusion of DIPG)	3 years and older	Tumour, tumour resection cavity or ventricular system
HER2	03500991	HER2-specific CAR T Cell Locoregional Immunotherapy for HER2+ Recurrent/Refractory Paediatric CNS Tumours	Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumour, ATRT, Primitive Neuroectodermal Tumour, Choroid Plexus Carcinoma, Pineoblastoma (exclusion of DIPG)	1 year to 26 years	tumour resection cavity or ventricular system
HER2	01109095	CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients with GBM (HERT-GBM)	Glioblastoma	Child, adult,	systemic
EGFR	03638167	EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR+ Recurrent or Refractory Paediatric CNS Tumours	Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumour, Atypical Teratoid/Rhabdoid Tumour, Primitive Neuroectodermal Tumour, Choroid Plexus Carcinoma, Pineoblastoma (exclusion of DIPG)	1 year to 26 years	tumour resection cavity or ventricular system
B7-H3	04185038	Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Paediatric Central Nervous System Tumours	Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumour, Atypical Teratoid/Rhabdoid Tumour Primitive Neuroectodermal Tumour, Choroid Plexus Carcinoma, Pineoblastoma, Childhood Glioma	1 year to 26 years	tumour resection cavity or ventricular system

Table data were searched at clinicaltrials.gov (21^st June 2021).